• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Athenex Inc. (Amendment)

    2/14/23 4:10:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNX alert in real time by email
    SC 13D/A 1 d466120dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

     

    ATHENEX, INC.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    04685N103

    (CUSIP Number)

    Johnson Y.N. Lau

    c/o Athenex, Inc.

    1001 Main Street, Suite 600

    Buffalo, New York 14203

    Telephone: (716) 898-8625

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule l3G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 04685N103

     

      1.    

      Names of reporting persons

     

      Johnson Y.N. Lau

      2.  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☐

     

      3.  

      SEC use only

     

      4.  

      Source of funds

     

      OO

      5.  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      Not Applicable

      6.  

      Citizenship or place of organization

     

      United States

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    with:

     

         7.     

      Sole voting power

     

      7,372,383(1)

         8.   

      Shared voting power

     

      1,005,890(2)

         9.   

      Sole dispositive power

     

      7,372,383(1)

       10.   

      Shared dispositive power

     

      1,005,890(2)

    11.    

      Aggregate amount beneficially owned by each reporting person

     

      8,378,273(1)(2)

    12.  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      Not Applicable

    13.  

      Percent of class represented by amount in Row (11)

     

      4.8%(3)

    14.  

      Type of reporting person

     

      IN

     

    1

    Includes 3,342,546 shares of common stock, par value $0.001 per share of Athenex, Inc. (the “Common Stock”) underlying options held by Johnson Y.N. Lau that vest within 60 days of December 31, 2022.

    2

    Consists of (a) 164,925 shares of Common Stock held by Dr. Lau’s spouse, (b) 678,880 shares of Common Stock held by Avalon Biomedical (Management) Limited (“Avalon”), (c) 107,181 shares of Common Stock held by Avalon Polytom (HK) Limited (“Avalon Polytom”), (d) 54,904 shares of Common Stock underlying presently exercisable options held by Avalon.

    3

    Based on 172,421,479 shares of Common Stock outstanding as of December 31, 2022.

     

    2


    Item 1.

    Security and Issuer.

    This Amendment No. 2 (this “Amendment”) amends the Schedule 13D filed by Johnson Y.N. Lau on April 27, 2018 and amended on October 9, 2020 with respect to shares of Common Stock of Athenex, Inc. (or the “Company”) as specifically set forth herein. The Company’s principal executive offices are located at 1001 Main Street, Suite 600, Buffalo, New York 14203.

     

    Item 2.

    Identity and Background.

    (a) This Amendment is being filed on behalf of Johnson Y.N. Lau, Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Reporting Person”).

    (b) The business address of the Reporting Person is c/o Athenex, Inc., 1001 Main Street, Suite 600, Buffalo, New York 14203.

    (c) The principal business of the Reporting Person is acting as Chief Executive Officer and Chairman of the Board of the Company.

    (d) – (e) During the last five years, the Reporting Person has not: (i) been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors), and (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) The Reporting Person is a citizen of the United States.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    On November 4, 2022, November 18, 2022, December 2, 2022, December 16, 2022, and December 30, 2022, the Reporting Person purchased 58,402, 58,762, 57,287, 96,284, and 77,288 shares of Common Stock, respectively, under a Salary Deduction and Stock Purchase Agreement with the Company (the “Agreement”) as previously reported by the Reporting Person pursuant to Section 16 of the Act. Under the Agreement, on each payroll date, the Reporting Person authorizes the Company to deduct a certain amount of his after-tax base salary to purchase shares of Common Stock from the Company at the Nasdaq Official Closing Price per share on that date.

     

    Item 4.

    Purpose of Transaction.

    Under the Agreement described in Item 3, the Reporting Person has purchased shares of Common Stock on each payroll date and will continue to do so until notice is given to the Company’s board of directors or until the termination of the Agreement. Depending on market conditions and other factors, the Reporting Person may purchase additional shares of Common Stock, or may sell or otherwise dispose of all or portions of his shares of Common Stock, if such sales and purchases would be consistent with the Reporting Person’s investment objectives.

    The Reporting Person is the Chief Executive Officer and Chairman of the Company. In such capacity, the Reporting Person may, from time to time, discuss or make plans or proposals to the Company’s management or other members of the Company’s board of directors with respect to the matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described in this Item 4, the Reporting Person does not have any present plans which relate to or would result in matters referred to in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5.

    Interest in Securities of the Issuer.

    (a) See rows (11) and (13) of the cover page to this Amendment for the aggregate number of shares of Common Stock and percentage of the shares of Common Stock beneficially owned by the Reporting Person.

     

    3


    (b) See rows (7) through (10) of the cover page to this Amendment for the number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

    (c) Except as set forth above in Item 3, the Reporting Person has not effected any transactions in Common Stock during the past 60 days.

    (d) The Reporting Person owns all of the outstanding interests in Creative Decade Global Limited, which owns 34.63% of the outstanding interests in Avalon Global Holdings Limited (“Avalon Global”). The Reporting Person serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares of Common Stock held by Avalon, an indirect wholly-owned subsidiary of Avalon Global. Avalon Polytom is a majority-owned affiliate of Avalon Global. Accordingly, certain other individuals who indirectly have a controlling interest in Avalon Global have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock held by Avalon and Avalon Polytom.

    (e) The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock as of December 31, 2022.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    None.

     

    Item 7.

    Material to be Filed as Exhibits.

     

    Exhibit    Description
    A    Form of Salary Deduction and Stock Purchase Agreement is incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2022.

     

    4


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2023

     

    /s/ Johnson Y.N. Lau

    Johnson Y.N. Lau
    Get the next $ATNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNX

    DatePrice TargetRatingAnalyst
    10/12/2021$8.00 → $5.00Outperform
    RBC Capital
    8/6/2021$9.00 → $8.00Outperform
    RBC Capital
    8/6/2021$5.00 → $4.00Market Perform
    SVB Leerink
    More analyst ratings

    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

      To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX) ("Athenex" or the "Company"), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceu

      5/14/23 11:15:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

      Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

      3/20/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Announces a Reverse Stock Split

      BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on November 22, 2022, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's common stock, at

      2/14/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Athenex Inc. (Amendment)

      SC 13D/A - Athenex, Inc. (0001300699) (Subject)

      2/14/23 4:10:55 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Athenex Inc.

      SC 13D - Athenex, Inc. (0001300699) (Subject)

      2/2/23 5:01:53 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Athenex Inc. (Amendment)

      SC 13G/A - Athenex, Inc. (0001300699) (Subject)

      2/14/22 3:50:00 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

      BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. "We are delighted to welcome Dr. Cohen to Athenex during this transformative period, as we strategically pivot to focus on advancing first-in-class

      6/8/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Announces Appointment of Chief Financial Officer

      BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. "The Board of Directors joins me in welcoming Joe to his new position as CFO," said Johnson Lau, Chief

      2/22/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FAMOTIDINE issued to ATHENEX INC

      Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

      1/12/22 4:41:30 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KLISYRI

      Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

      12/20/20 4:30:55 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    SEC Filings

    See more
    • Athenex Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      10/2/23 7:42:29 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Inc. filed SEC Form 8-K: Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      8/17/23 4:06:01 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      7/18/23 9:03:58 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Lau Johnson Yiu Nam

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:36:36 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kwan Rudolf

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:33:18 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cook Timothy Devere

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:29:48 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on Athenex with a new price target

      RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $5.00 from $8.00 previously

      10/12/21 6:58:34 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Athenex with a new price target

      RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $8.00 from $9.00 previously

      8/6/21 9:52:27 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Athenex with a new price target

      SVB Leerink reiterated coverage of Athenex with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously

      8/6/21 5:46:15 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Financials

    Live finance-specific insights

    See more
    • Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

      Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

      3/20/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

      BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: 1-844-826-3033 International: 1-412-317-5185 Pass

      10/24/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Provides Second Quarter 2022 Financial Results and Business Update

      Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respectivelyMaintains full-year 2022 product revenue guidance range of 20-25% growth year-over-year Management to host conference call and webcast today at 8:00 a.m. EDT BUFFALO, N.Y.

      7/28/22 7:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care